Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.

European journal of haematology - 1 Dec 2016

Knittel Gero, Liedgens Paul, Korovkina Darya, Pallasch Christian P, Reinhardt Hans Christian

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma in the Western world and remains a clinical challenge. Two types of DLBCL are distinguishable, namely a germinal center B-cell-like phenotype (GCB) and an activated B-cell-like phenotype (ABC). Particularly ABC-DLBCL is difficult to treat, as this subentity typically displays resistance against frontline chemo-immune therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CARD Signaling Adaptor Proteins
Share to CD79 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Guanylate Cyclase

Share to Lymphoma, Large B-Cell, Diffuse

Share to Myeloid Differentiation Factor 88

Share to Plasma Cells

Share to Tumor Necrosis Factor alpha-Induced Protein 3

Source

Identifiers

PMID: 27526684
DOI: 10.1111/ejh.12792

Genes

BCL2
CARD11
MYD88

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.PMID 27526684Read ↗

Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Molecular Pathogenesis of Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic ImplicationsSemantic proximity Read ↗

Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.Semantic proximity Read ↗

Distinct Genetically Determined Origins of Myd88 / BCL2 -Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention StrategiesSemantic proximity Read ↗

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.Semantic proximity Read ↗

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.Semantic proximity Read ↗

The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphomaSemantic proximity Read ↗

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in miceSemantic proximity Read ↗

Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.Semantic proximity Read ↗

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.